Prosecution Insights
Last updated: October 02, 2026

Examiner: ELKINS, BLAKE HARRISON

Tech Center 1600 • Art Units: 1656 1684 1687

This examiner grants 100% of resolved cases

Analysis

Blake Harrison Elkins has a very limited record in Art Unit 1656 with only 1 resolved case. This single case resulted in an allowance rate of 100.0 percent and had a median days to allowance of 1539. The interview lift is currently 0.0 percent. Because these metrics are based on just 1 case in Tech Center 1600, they do not yet establish a broad pattern for future prosecution. The 1539 days to allowance is the only data point available for timing.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

100.0%
Allow Rate
+40.0% vs TC avg
22
Total Applications
+0.0%
Interview Lift
1539
Avg Prosecution Days
Based on 1 resolved cases, 2023–2026

Rejection Statute Breakdown

19.4%
§101 Eligibility
8.7%
§102 Novelty
36.2%
§103 Obviousness
15.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17948695 EXCRETA DETERMINATION METHOD, EXCRETA DETERMINATION DEVICE, AND NON-TRANSITORY COMPUTER READABLE RECORDING MEDIUM STORING EXCRETA DETERMINATION PROGRAM Final Rejection PANASONIC HOLDINGS CORPORATION
18343857 METHODS FOR ASSESSING GENOMIC INSTABILITY Non-Final OA Life Technologies Corporation
17743009 ADJUSTMENT METHOD FOR AN ANALYTICAL DETERMINATION OF AN ANALYTE IN A BODY FLUID Final Rejection Roche Diabetes Care, Inc.
17995250 SYSTEMS AND METHODS FOR GUT MICROBIOME PRECISION MEDICINE Final Rejection The Regents of the University of California
17960500 METHOD FOR PREDICTING RETROSYNTHESIS OF A COMPOUND MOLECULE AND RELATED APPARATUS Non-Final OA TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
17956141 CLINICAL OMICS DATA PROCESSING METHOD AND APPARATUS BASED ON GRAPH NEURAL NETWORK, DEVICE AND MEDIUM Final Rejection TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED
18102202 DIFFERENTIATION OF COINFECTION FROM CONTAMINATION WITHIN GENETIC SAMPLES Non-Final OA Helix, Inc.
18385604 METHOD AND SYSTEM FOR DESIGNING DRUG-LIKE MOLECULES FROM DESIRED GENE EXPRESSION SIGNATURES Non-Final OA Tata Consultancy Services Limited
17810844 Method and an apparatus for predicting a future state of a biological system, a system and a computer program Non-Final OA Leica Microsystems CMS GmbH
18007241 SYSTEM AND METHOD FOR PRIME EDITING EFFICIENCY PREDICTION USING DEEP LEARNING Non-Final OA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
18176375 SYSTEM, METHOD, AND COMPUTER READABLE STORAGE MEDIUM FOR AUTO-REGRESSIVE WAVENET VARIATIONAL AUTOENCODERS FOR ALIGNMENT-FREE GENERATIVE PROTEIN DESIGN AND FITNESS PREDICTION Non-Final OA University of Chicago
18281025 PROFILING EPIGENETIC AGE IN SINGLE CELLS AND WITH LOW-PASS SEQUENCING DATA Non-Final OA The Brigham and Women's Hospital, Inc.
18340795 SPLIT-READ ALIGNMENT BY INTELLIGENTLY IDENTIFYING AND SCORING CANDIDATE SPLIT GROUPS Non-Final OA Illumina, Inc.
18059326 GENERATING CLUSTER-SPECIFIC-SIGNAL CORRECTIONS FOR DETERMINING NUCLEOTIDE-BASE CALLS Non-Final OA Illumina, Inc.
17997633 GENOME SEQUENCING AND DETECTION TECHNIQUES Non-Final OA ILLUMINA, INC.
18378471 SYSTEMS AND METHODS FOR PATIENT CLASSIFICATION Non-Final OA GENFIT

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month